CALIPER LIFE SCIENCES RECOGNIZED BY DELOITTE & TOUCHE AS ONE OF THE NATION’S FASTEST GROWING TECHNOLOGY COMPANIES

December 18, 2007

- Company  Attributes Recognition to Quality of Intellectual Property Estate -

HOPKINTON, Mass., December 18, 2007 -- Caliper Life Sciences, Inc. (NASDAQ: CALP) today announced that it has been recognized as one of the “Technology Fast 500” by Deloitte & Touche, LLP. This nationwide ranking recognizes innovative companies fueling technological advancements. Caliper ranked 435 on the national list and was also recognized as one of the New England “Fast 50” companies. “In the past several years we have invested heavily in R&D as well as technology-based acquisitions. The result is a suite of fast growing products and services with an extensive intellectual property estate encompassing cutting edge technologies designed to improve the success rate of pharmaceutical drug discovery by bridging in vitro and in vivo research efforts,” said Kevin Hrusovsky, President and CEO of Caliper. “This award by Deloitte & Touche recognizes the traction we are achieving with our strategy and speaks to the importance of our dedicated employees in their pursuit of our corporate mission—improving the quality of human life by linking discontinuous technologies with important discovery applications in oncology, inflammation, infectious disease, metabolic, CNS and cardiovascular disease areas.” The Technology Fast 500 identifies the 500 fastest-growing technology, media and entertainment, telecommunications and life sciences companies in the United States and Canada. In addition to Caliper, this year’s winners, selected from nominations and extensive research, included Google, Amylin Pharmaceuticals, Sirius Satellite Radio, Cubist Pharmaceuticals and Biogen Idec, among many others. 

About Caliper Life Sciences
Caliper Life Sciences is a premier provider of leading-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper’s portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit www.caliperLS.com. 

About Deloitte
Deloitte refers to one or more of Deloitte Touche Tohmatsu, a Swiss Verein, its member firms and their respective subsidiaries and affiliates. As a Swiss Verein (association), neither Deloitte Touche Tohmatsu nor any of its member firms has any liability for each other’s acts or omissions. Each of the member firms is a separate and independent legal entity operating under the names “Deloitte”, “Deloitte & Touche”, “Deloitte Touche Tohmatsu” or other related names. Services are provided by the member firms or their subsidiaries or affiliates and not by the Deloitte Touche Tohmatsu Verein.  Deloitte & Touche USA LLP is the US member firm of Deloitte Touche Tohmatsu. In the US, services are provided by the subsidiaries of Deloitte & Touche USA LLP (Deloitte & Touche LLP, Deloitte Consulting LLP, Deloitte Financial Advisory Services LLP, Deloitte Tax LLP and their subsidiaries), and not by Deloitte & Touche USA LLP.

 

Contacts:
Robert Halpern
Caliper Life Sciences
774.278.2371
robert.halpern@caliperLS.com
 
Stacey Holifield or Melissa Bruno
Schwartz Communications
781.684.0770
caliper@schwartz-pr.com